Future Meat listed on SVG Ventures THRIVE Top 50 AgTech & FoodTech Cos worldwide
Future Meat Technologies was listed among two separate lists highlighting the top 50 companies worldwide in the Foodtech and Agtech (agriculture tech) sectors in 2020,
Argaman Technologies Viral Deactivation Face Masks to Hong Kong to fight Coronavirus!
Jerusalem based Argaman Technologies, Ltd. presents its Viral Deactivation Face Masks which are headed to Hong Kong to fight the Coronavirus. The Argaman Face Masks
RenalSense starts Delivery of its First Orders of Clarity RMS in Europe
RenalSense has started commercial sales of its Clarity RMS™ system in Europe with its distribution partner Fresenius Medical Care (Bad Homburg). The Clarity RMS received
Genetika+ Won Three International Awards in 2019!
Genetika + is a Jerusalem based biotech start-up developing cutting edge technology to determine which anti-depressant is best suited to each patient. When Treating a
Good News from the NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax’s M-001 Universal Influenza Vaccine Candidate
Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax’s M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials Data published on Clinicaltrials.gov
Successful BrainsWay Pivotal Multicenter Study Evaluating Deep Transcranial Magnetic Stimulation System as Smoking Cessation Aid
BrainsWay Ltd. achieved final positive results from its pivotal multicenter trial on the safety and efficacy of the Company’s H4 Deep transcranial magnetic stimulation system
Finally, a Pill that Could Fix the Cause of Type2 Diabetes
Zygosid-50, a drug under development in Israel, could be the first to treat type 2 diabetes by restoring the body’s insulin sensitivity, without side effects.
Augmedics Announces U.S. Launch of xvision, First Augmented Reality Surgery Guidance System
Augmedics, a pioneer in augmented reality surgical image guidance, has announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the U.S. launch of its
Novelstem Increases Newstem Ownership to 27.3%
Following achievement of an important milestone for Stem-Cell based cancer treatments resistance diagnostics, Jerusalem based NewStem received a further $ 1 million follow-on investment from
